SynthesisFrontiers in pharmacology2025
Effects of phytosterol-rich foods on lipid profile and inflammatory markers in patients with hyperlipidemia: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Dietary and Formulation Potential of Natural Oils and Fats in Ocular Health and Disease: Mechanisms, Evidence, and Future Directions.Nutrients · 2026Review
- Beyond Phytosterol Profiling in Greek Olive Oil: Biological Variability, Regulatory Interpretation and the Near-Threshold Sterolic Space.Molecules (Basel, Switzerland) · 2026Review
- Soursop-Derived Gut Metabolites Restore Adipose Metabolic Homeostasis and Attenuate Fructose-Induced Adipotoxicity: Mechanistic Insights into the Soursop-Gut-Adipose Axis.Antioxidants (Basel, Switzerland) · 2026Article
- Article
- Functional Foods as Vehicles for Bioactive Compounds: Chemical and Nutritional Perspectives on Health and Disease Prevention.International journal of molecular sciences · 2026Review
- Anticancer Molecular Mechanisms of Phytosterols: An Updated Review on Clinical Trials.Food science & nutrition · 2026Review
- Nutritional and Metabolic Interventions to Prevent and Treat Protein-Energy Wasting in Nondialysis CKD-Narrative Review.Nutrients · 2026Review
- Identification of gemilukast as a bifunctional molecule with lipid-lowering and anti-inflammatory activities.Frontiers in immunology · 2026Article
- Association of the atherogenic index of plasma with in-hospital mortality in patients with sepsis-induced coagulopathy.Lipids in health and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As naturally occurring compounds in plant-based foods, phytosterols have attracted attention for their lipid-modulating potential and proposed role as adjunctive therapies in managing hyperlipidemia. Nevertheless, conflicting evidence persists regarding their dual impact on dyslipidemia and subclinical inflammation. Objective: This systematic review aimed to assess the impact of phytosterol-rich foods on lipid metabolism and inflammatory responses in hyperlipidemic populations. Methods: A thorough literature search was performed across nine databases (including China National Knowledge Infrastructure Wanfang Data, VIP, SinoMed, PubMed, Cochrane Library, Embase, Scopus, Web of Science) from their inception up to 15 February 2025. Studies included were randomized controlled trials evaluating phytosterol interventions in adults with hyperlipidemia. The quality of the included studies was evaluated using the Cochrane Randomized Trial Risk Bias Tool, and Data analysis was performed using RevMan 5.4. Results: This study included 14 randomized controlled trials with a total of 1,088 participants. The pooled results demonstrated statistically significant reductions in total cholesterol (TC) levels (mean difference (MD) = -0.65, 95% CI -0.83 to -0.47, Conclusion: Phytosterol intervention demonstrates significant efficacy in modulating atherogenic lipid profiles, such as TC and LDL-C, while also elevating HDL-C levels in individuals with hyperlipidemia. Yet, it fails to demonstrate anti-inflammatory activity as measured by CRP levels. The observed marginal TG-lowering effect should be interpreted with caution given substantial interstudy heterogeneity. Therefore, larger, metabolomics-inclusive studies are required for definitive conclusions and clinical guidance. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/#loginpage, identifier CRD420251002645.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.